ACADIA Pharmaceuticals’ (ACAD) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research report report published on Thursday morning,Benzinga reports. Cantor Fitzgerald currently has a $28.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.15 EPS.

ACAD has been the topic of several other research reports. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target on the stock. StockNews.com cut shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $19.34 on Thursday. The business has a 50-day moving average of $18.37 and a 200-day moving average of $16.81. The company has a market capitalization of $3.22 billion, a PE ratio of 24.79 and a beta of 0.37. ACADIA Pharmaceuticals has a 1-year low of $14.15 and a 1-year high of $25.20.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Virtus Fund Advisers LLC bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $39,000. R Squared Ltd bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $47,000. Quest Partners LLC raised its holdings in shares of ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,047 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $64,000. Finally, KBC Group NV raised its holdings in shares of ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 2,044 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.